论文部分内容阅读
目的探讨缺血性脑病的临床治疗效果。方法选择2011年10月～2012年10月在我院治疗的48例患者,选择脑梗死(CI)组19例,脑动脉硬化(CA)组15例,椎-基底动脉供血不足组(CASI)14例,对照组:选取同其健康人18例,男性10例,女性8例,年龄39～80岁,年龄平均64岁,排除心、脑、肾疾病及内分泌疾病。结果内皮素可使血管收缩或痉挛,影响脑的血流。结论特异灶ET受体拮抗剂的研究,将为缺血性脑病治疗开拓新领域[2],有助于了解血管内皮细胞损伤,预防疾病发生以及改善预后。
Objective To investigate the clinical effect of ischemic encephalopathy. Methods Forty-eight patients were treated in our hospital from October 2011 to October 2012. Nineteen patients with cerebral infarction (CI), 15 patients with cerebral arteriosclerosis (CA), 15 patients with vertebrobasilar insufficiency (CASI) 14 cases and control group: 18 healthy subjects, 10 males and 8 females were selected, aged from 39 to 80 years and average age was 64 years old, excluding heart, brain and kidney diseases and endocrine diseases. Endothelin can cause vasoconstriction or spasm, affecting brain blood flow. Conclusion The study of specific receptor antagonist of ET will open up a new field for the treatment of ischemic encephalopathy [2], help to understand the damage of vascular endothelial cells, prevent the occurrence of diseases and improve the prognosis.